Introduction {#section5-2050312118781895}
============

Dermatomyositis (DM) and polymyositis (PM) are the two main subtypes of idiopathic inflammatory myopathy. The association between DM/PM and malignancies has been well established.^[@bibr1-2050312118781895]^ Previous population-based studies showed standardized incidence ratio of malignancies to be higher in DM/PM patients than in normal population, with the malignancy risk greater in DM than in PM.^[@bibr2-2050312118781895]^ The most common malignancy associated with DM/PM varied in different geographical areas and ethnics, with nasopharyngeal carcinoma (NPC) the most common among DM/PM patients in China, Taiwan and Southeast Asian countries.^[@bibr3-2050312118781895][@bibr4-2050312118781895][@bibr5-2050312118781895]--[@bibr6-2050312118781895]^ Contrary, the common malignancies associated with DM/PM in European countries were colon, lung and ovarian cancer.^[@bibr7-2050312118781895][@bibr8-2050312118781895]--[@bibr9-2050312118781895]^

To date, there is no consensus on the screening for malignancies in DM/PM. Suggested surveys for malignancies included computed tomography (CT) of the thorax, abdomen and pelvis, mammography, gynecological examination and nasopharynx assessment.^[@bibr4-2050312118781895],[@bibr8-2050312118781895],[@bibr10-2050312118781895],[@bibr11-2050312118781895]^ A more advanced imaging, positron emission tomography/computer tomography (PET/CT) had shown its ability to detect occult malignancies in DM/PM patients; however, the ultimate diagnosis still needing histopathology confirmation.^[@bibr12-2050312118781895],[@bibr13-2050312118781895]^ The usefulness of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125) in detecting malignancies in DM/PM patients has been assessed. Although Amoura et al.^[@bibr14-2050312118781895]^ reported that CA125 and CA19-9 could be useful tumor markers, a more recent study did not show any association of these tumor markers with malignancies in DM/PM patients.^[@bibr15-2050312118781895]^ The utility of these tumor markers in screening for occult malignancies in DM/PM remains controversial. Myositis-specific autoantibodies (MSA) such as anti-transcriptional intermediary factor-1 gamma (anti-TIF1 γ), anti-nuclear matrix protein 2 (anti-NXP2) and anti-melanoma differentiation gene 5 (anti-MDA5) were reported to have an increased risk of malignancies in DM/PM patients.^[@bibr16-2050312118781895][@bibr17-2050312118781895]--[@bibr18-2050312118781895]^ However, these MSA were not easily available in Taiwan.

The incidence of interstitial lung disease (ILD) is notably higher than the incidence of malignancies in DM/PM patients. ILD may occur in up to 65% of DM/PM patients at diagnosis.^[@bibr19-2050312118781895]^ Therefore, a more promising marker to detect the occurrence of ILD is essential. Elevated tumor markers were observed in patients with ILD.^[@bibr20-2050312118781895][@bibr21-2050312118781895]--[@bibr22-2050312118781895]^ However, the clinical implication of tumor markers in relation to ILD is still ambiguous.

In view of the most prevalent malignancy associated with DM/PM in Taiwan was NPC, and there was no specific conventional tumor marker which can accurately detect or monitor this malignancy at present, we hypothesized that measuring these tumor markers may not be essential as part of malignancy screening for Taiwanese patients with DM/PM. To our knowledge, there is no previous study investigating the associations of tumor markers with the occurrence of malignancies or ILD in Chinese patients with DM/PM. Therefore, we aim to examine the usefulness of tumor markers in DM/PM patients in Taiwan.

Methodology {#section6-2050312118781895}
===========

Data source {#section7-2050312118781895}
-----------

Data were collected retrospectively from the database of Taichung Veterans General Hospital, a tertiary medical center in Taiwan, using the Hyperion Enterprise Performance Management System (Oracle, Redwood City, CA, USA). DM/PM patients fulfilling the Bohan and Peter^[@bibr23-2050312118781895]^ criteria and diagnosed with *International Classification of Diseases, 9th Revision, Clinical Modification* (ICD-9-CM) code for DM/PM (710.3 for DM and 710.4 for PM)^[@bibr24-2050312118781895]^ were identified from the hospital registry. This study was conducted in accordance with the Helsinki Declaration and was approved by the Institution Review Board of Taichung Veterans General Hospital, Taiwan (IRB number: CG13104-1). This retrospective cohort was a sub-study of a previous DM/PM study.^[@bibr25-2050312118781895]^ The written informed consents were obtained from all subjects prior to starting the study.

Study population {#section8-2050312118781895}
----------------

All adult DM/PM patients older than 18 years of age who possessed catastrophic illness certification for DM/PM in the period from 1 January 1998 to 31 December 2014 were recruited. To own the DM/PM catastrophic illness certification in Taiwan, patients must be evaluated by at least two experienced rheumatologists examining the detailed medical history, clinical symptoms, laboratory investigations and imaging. We excluded patients who had malignancies prior to the diagnosis of DM/PM. Patients who had not been checked for any serum tumor marker after the diagnosis of DM/PM were also not eligible for this analysis ([Figure 1](#fig1-2050312118781895){ref-type="fig"}). PET/CT were not included in our study because the test is not routinely done. The cost of PET/CT is high in Taiwan, and it is not reimbursed by Taiwan National Health Insurance. MSA were also not reviewed in our study because these tests were not available during the recruitment period. The sample size was calculated using SamplePower software version 2.0 with alpha level set at 0.05 and the power set at 0.8. The minimal subjects required in malignancy and non-malignancy were 13 each, with the assumption of positive tumor markers in malignancy patients was 0.5 and in non-malignancy patients was 0.03.^[@bibr14-2050312118781895]^

![Flowchart of patients' selection in this hospital-based cohort study.](10.1177_2050312118781895-fig1){#fig1-2050312118781895}

Tumor markers assays {#section9-2050312118781895}
--------------------

Up to now, there is no protocol in malignancies screening for DM/PM patients locally and internationally. The tumor markers used in this cohort were all based on the clinician judgments. Tumor markers evaluated in this study were serum CEA, CA125, CA19-9, CA15-3 and alpha-fetoprotein (AFP) on the first sample taken within 1 month after the diagnosis of DM/PM. CA125, CA19-9 and CA15-3 were measured with the electro-chemiluminescence immunoassay of Roche Diagnostics Cobas e601 (Roche, Mannheim, Germany); CEA and AFP with an immunoradiometric assay kit (Cisbio Bioassays, Codolet, France). The normal ranges for tumor markers were CEA \< 5.0 ng/mL, CA125 \< 35.0 U/mL, CA19-9 \< 34.0 U/mL, CA15-3 \< 25 U/mL and AFP \< 12 ng/mL.

Study outcome {#section10-2050312118781895}
-------------

The primary outcome was the detection of malignancies after the diagnosis of DM/PM. Malignancies were identified using ICD-9-CM (140.x--172.x, 174.x--195.8 and 200.x--208.x).^[@bibr26-2050312118781895]^ The diagnoses of malignancy were further confirmed by the histopathology evidence available. We also determined the occurrence of ILD (ICD-9-CM 515 and 516.3),^[@bibr27-2050312118781895]^ which was confirmed by the presence of abnormalities on high-resolution CT (HRCT) scan of the lung examined by well-trained radiologist blinded to the data of tumor markers. Abnormalities on HRCT of ILD included sub-pleural honeycombing, bronchiectasis, ground glass opacities, cryptogenic organizing pneumonia pattern, consolidation and pneumomediastinum.^[@bibr28-2050312118781895]^

Statistical analysis {#section11-2050312118781895}
--------------------

Demographic data were presented as mean ± standard deviation for continuous variables, and as number of cases and percentage in categorical variables. Chi-square test or Fisher's exact test was used in comparing the variables. Data were presented as odds ratio (OR) with 95% confidence interval (CI). Statistical Package for the Social Sciences (SPSS) version 22.0 software (SPSS, Chicago, IL, USA) was used to analyze the data. Significant p value was set at \<0.05.

Results {#section12-2050312118781895}
=======

Demographic data {#section13-2050312118781895}
----------------

In total, 151 patients were enrolled in this study ([Figure 1](#fig1-2050312118781895){ref-type="fig"}). Of them, 98 (64.9%) were DM and 53 (35.1%) were PM patients. The majority of patients were female (65.6%). The mean age of the patients was 47.7 ± 13.6 years. A total of 368 tumor marker tests were done. The most commonly ordered tumor markers in this study were CEA and AFP with 26.6% and 26.1% respectively. Among the tumor markers done, only 13.3% showed elevated results.

The clinical utility of tumor markers in detecting malignancies {#section14-2050312118781895}
---------------------------------------------------------------

A total of 15 malignancies were detected in this study ([Table 1](#table1-2050312118781895){ref-type="table"}). Among the patients with malignancies, 13 (86.7%) were DM and 2 (13.3%) were PM. The most common malignancy observed in this study was breast ductal carcinoma (n = 4) followed by bladder transitional cell carcinoma (n = 2), lung adenocarcinoma (n = 2), cervical intraepithelial neoplasia 3 and papillary squamous cell carcinoma (n = 2), colorectal carcinoma (colon and rectal adenocarcinoma) (n = 2), uterine adenocarcinoma (n = 1), NPC (n = 1) and hematological malignancy (myelodysplastic with excess blast cells) (n = 1). The mean age of malignancy diagnosed was 50.2 ± 11.6 years. Majority of the malignancies (60%) were detected more than 3 years after the diagnosis of DM/PM. The mean duration of occurrence of malignancies from DM/PM diagnosis was 6.05 ± 5.69 years. Among the patients with malignancies, three had concomitant ILD.

###### 

Demographic data and clinical characteristics of dermatomyositis (DM)/polymyositis (PM) patients with malignancies.

![](10.1177_2050312118781895-table1)

       Gender   Diagnosis   Age of diagnosis (years)   Cancer type                                Cancer diagnosis interval (years)   Relevant tumor markers   Concomitant ILD
  ---- -------- ----------- -------------------------- ------------------------------------------ ----------------------------------- ------------------------ -----------------
  1    F        PM          52.5                       Breast ductal carcinoma                    11.14                               CEA (--), CA15-3 (--)    No
  2    F        DM          36.9                       Breast ductal carcinoma                    8.96                                CEA (--), CA15-3 (--)    No
  3    F        DM          45.5                       Breast ductal carcinoma                    5.71                                CEA (--), CA15-3 (--)    No
  4    F        DM          57.3                       Breast ductal carcinoma                    0.77                                CEA (--), CA15-3 (--)    No
  5    F        DM          56.5                       Bladder transitional cell carcinoma        10.46                               CEA (+)                  No
  6    M        DM          77.1                       Bladder transitional cell carcinoma        2.35                                NR                       No
  7    F        DM          45.2                       Lung adenocarcinoma                        3.59                                CEA (--)                 No
  8    M        DM          44.1                       Lung adenocarcinoma                        0.04                                CEA (+)                  No
  9    F        DM          25.8                       Cervical intraepithelial neoplasia 3       4.38                                CEA (--), AFP (ND)       No
  10   F        DM          56.9                       Cervix papillary squamous cell carcinoma   0.00                                CEA (--), AFP (--)       No
  11   F        DM          41.2                       Uterine adenocarcinoma                     0.97                                CEA (--), AFP (--)       No
  12   M        DM          55.3                       Nasopharyngeal carcinoma                   0.02                                NR                       Yes
  13   F        DM          50.1                       Rectal adenocarcinoma                      16.89                               CEA (--)                 Yes
  14   M        DM          56.7                       Colon adenocarcinoma                       14.58                               CEA (+), CA19-9 (+)      No
  15   F        PM          51.6                       Myelodysplastic with blast cells           10.90                               NR                       Yes

F: female; M: male; ILD: interstitial lung disease; CEA: carcinoembryonic antigen; CA15-3: carbohydrate antigen 15-3; (--): negative; (+): positive; NR: not relevant; AFP: alpha-fetoprotein; ND: not done.

### CA15-3 {#section15-2050312118781895}

Among the 34 patients screened for CA15-3, 9 (26.5%) showed elevated results. None of these patients with elevated results developed a malignancy (p = 0.293; OR: 0.80; 95% CI: 0.66--0.97) ([Table 2](#table2-2050312118781895){ref-type="table"}).

###### 

The association of tumor markers and malignancies in dermatomyositis/polymyositis patients.^[a](#table-fn4-2050312118781895){ref-type="table-fn"}^

![](10.1177_2050312118781895-table2)

  Malignancy    Odds ratio (95% CI)                                    
  ------------- --------------------- ------------- ------- ------- -- --------------------
  Age (years)   47.4 ± 13.9           50.2 ± 11.6   0.448              
  Gender        0.703                                                  
   Male         48                    35.3          4       26.7       
   Female       88                    64.7          11      73.3       
  CA15-3        0.293                                                  
   Negative     20                    69.0          5       100.0      
   Positive     9                     31.0          0       0.0        0.80 (0.66--0.97)
  CA125         1.000                                                  
   Negative     51                    75.0          2       66.7       
   Positive     17                    25.0          1       33.3       1.50 (0.13--17.60)
  AFP           1.000                                                  
   Negative     88                    95.7          4       100.0      
   Positive     4                     4.3           0       0.0        0.96 (0.92--1.00)
  CEA           0.085                                                  
   Negative     79                    94.0          11      78.6       
   Positive     5                     6.0           3       21.4       4.31 (0.90--20.59)
  CA19-9        0.474                                                  
   Negative     56                    86.2          3       75.0       
   Positive     9                     13.8          1       25.0       2.07 (0.19--22.19)

CI: confidence interval; CA: carbohydrate antigen; CEA: carcinoembryonic antigen; AFP: alpha-fetoprotein.

p values were determined by Fisher's exact test.

Values are mean ± standard deviation or the number (n) of patients.

### CA125 {#section16-2050312118781895}

Of 71 patients tested for CA125, 18 (25.4%) showed positive results. Only a patient with positive result had malignancy (uterine carcinoma) (p = 1.000; OR: 1.50; 95% CI: 0.13--17.60).

### CA19-9 {#section17-2050312118781895}

Among 69 patients who were tested for CA19-9, 10 (14.5%) had elevated results. One of the patients with positive results developed malignancy (colon carcinoma) (p = 0.474; OR: 2.07; 95% CI: 0.19--22.19).

### AFP {#section18-2050312118781895}

In total, 96 patients were tested for AFP, 4 (4.2%) showed elevated results. None of these patients with elevated results developed a malignancy (p = 1.000; OR: 0.96; 95% CI: 0.92--1.00).

### CEA {#section19-2050312118781895}

In total, 98 patients were screened for CEA, 8 (8.2%) showed positive results. Of these patients with positive results, three developed malignancies (two lung carcinoma and one colon carcinoma) (p = 0.085; OR: 4.31; 95% CI: 0.90--20.59).

The clinical utility of tumor markers in detecting ILD {#section20-2050312118781895}
------------------------------------------------------

In this cohort, 61 (40.4%) patients developed ILD including 46 (75.4%) DM and 15 (24.6%) PM patients. The mean age of developing ILD was 49.0 ± 11.0 years. There were 28 (45.9%) of ILD detected within 1 year after the diagnosis of DM/PM. Anti-Jo1 antibody positivity was significantly associated with the presence of ILD (p \< 0.001; OR: 10.15; 95% CI: 3.27--31.57). Among the patients who had elevated serum CA15-3, the majority (88.9%) developed ILD (p = 0.006; OR: 17.00; 95% CI: 1.81--160.05) ([Table 3](#table3-2050312118781895){ref-type="table"}). Otherwise, tumor markers such as CA125, CA19-9, CEA and AFP showed no significant association with the presence of ILD.

###### 

The association of tumor markers and interstitial lung disease in dermatomyositis/polymyositis patients.^[a](#table-fn6-2050312118781895){ref-type="table-fn"}^

![](10.1177_2050312118781895-table3)

  Interstitial lung disease                                                     
  --------------------------- ----------------- ------------- ------- ------ -- ----------------------
  Age (years)                 46.8 ± 15.2       49.0 ± 11.0   0.306             
  Gender                      0.116                                             
   Male                       36                40.0          16      26.2      
   Female                     54                60.0          45      73.8      
  CA15-3                      **0.006**                                         
   Negative                   17                94.4          8       50.0      
   Positive                   1                 5.6           8       50.0      17.00 (1.81--160.05)
  CA125                       0.305^b^                                          
   Negative                   30                81.1          23      67.6      
   Positive                   7                 18.9          11      32.4      2.05 (0.69--6.11)
  AFP                         1.000                                             
   Negative                   49                96.1          43      95.6      
   Positive                   2                 3.9           2       4.4       1.14 (0.15--8.44)
  CEA                         0.273                                             
   Negative                   54                94.7          36      87.8      
   Positive                   3                 5.3           5       12.2      2.50 (0.56--11.12)
  CA19-9                      0.737                                             
   Negative                   30                83.3          29      87.9      
   Positive                   6                 16.7          4       12.1      0.69 (0.18--2.70)
  Anti-Jo1                    **\<0.001** ^b^                                   
   Negative                   72                94.7          39      63.9      10.15 (3.27--31.57)
   Positive                   4                 5.3           22      36.1      

CI: confidence interval; CA: carbohydrate antigen; CEA: carcinoembryonic antigen; AFP: alpha-fetoprotein.

Values are mean ± standard deviation or the number (n) of patients.

p values were determined by Fisher's exact test and ^b^Chi-square test.

The bold values are significant p values.

Discussion {#section21-2050312118781895}
==========

In this hospital-based cohort study of 151 DM/PM patients, we have observed 15 cases (9.9%) of malignancies; 13 (13.3%) with DM and 2 (3.8%) with PM. This observation was in agreement with the results from previous reports.^[@bibr1-2050312118781895],[@bibr14-2050312118781895]^ Compared to another population-based study,^[@bibr3-2050312118781895]^ our results showed a higher proportion of malignancies in DM. This discrepancy might be due to the patient selection criteria of the study that some patients were excluded, hence reduced the denominators of DM. There was no significant association of elevated tumor markers with the occurrence of malignancies in DM/PM patients ([Tables 1](#table1-2050312118781895){ref-type="table"} and [2](#table2-2050312118781895){ref-type="table"}), which was consistent with the results demonstrated by Andráás et al.^[@bibr15-2050312118781895]^ and supported by several international recommendations that tumor markers are not useful for malignancy screening.^[@bibr29-2050312118781895][@bibr30-2050312118781895][@bibr31-2050312118781895][@bibr32-2050312118781895]--[@bibr33-2050312118781895]^ American Society of Clinical Oncology stated that CEA is not recommended as a screening for colorectal cancer,^[@bibr29-2050312118781895]^ and there was insufficient data to suggest CA15-3 as a screening test for breast cancer.^[@bibr30-2050312118781895]^ Similarly, National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines did not recommend CEA, CA15-3 and CA125 testing as the screening for colorectal, breast and ovaries cancers, respectively.^[@bibr31-2050312118781895]^ According to American Association for the Study of Liver Diseases and the Asian Pacific Association for the Study of the Liver, AFP alone is also insufficient for the diagnosis of hepatocellular carcinoma.^[@bibr32-2050312118781895],[@bibr33-2050312118781895]^ However, opposed to our results, previous studies demonstrated a significant association of raised tumor markers with malignancies in DM/PM patients.^[@bibr14-2050312118781895],[@bibr34-2050312118781895],[@bibr35-2050312118781895]^

Interestingly, CA15-3 level was significantly higher in many DM/PM patients, with its raised levels associated with a 17-fold risk of ILD (p = 0.006; OR: 17.00; 95% CI: 1.81--160.05). None of the ILD patients with elevated CA15-3 developed malignancy. These findings were consistent with the observation from previous studies that CA15-3 may be increased in patients with collagen-vascular diseases and ILD, but without occurrence of malignancy.^[@bibr21-2050312118781895],[@bibr22-2050312118781895]^ The employed monoclonal antibodies in CA15-3 assay recognized amino acids sequences on the central protein core of mucin-1.^[@bibr21-2050312118781895]^ The mucin-1 is a high-weight glycoprotein which is expressed on the surface of various epithelial cells such as type II pneumocytes,^[@bibr36-2050312118781895]^ hence explains the association of elevated CA15-3 levels with the presence of ILD. Krebs von den Lungen-6 (KL-6), an important serum marker used in detecting ILD, was also noted to be specific to mucin-1. Kruit et al.^[@bibr37-2050312118781895]^ demonstrated that both CA15-3 and KL-6 were equally sensitive and specific for pulmonary fibrosis associated with ILD. Although other studies had reported the association between ILD and other tumor markers such as CEA and CA19-9,^[@bibr20-2050312118781895],[@bibr38-2050312118781895]^ these associations were not observed in our study.

In the previous studies based on population from 1997 to 2007, the most common malignancy associated with DM/PM in Taiwan was NPC.^[@bibr3-2050312118781895],[@bibr24-2050312118781895]^ Increased awareness of the NPC risk such as betel nut chewing, smoking, consuming preserved food and the implementation of cancer screening program may help in reducing NPC incidence.^[@bibr39-2050312118781895]^ In contrast, the incidence of breast cancer showed a rising trend possibly due to the westernization of lifestyle in Taiwan.^[@bibr40-2050312118781895]^ These could probably explain the trend of the breast cancer replacing NPC as the most common malignancy associated with DM/PM patients in this study.

Our study has several limitations. First, the misclassification and misdiagnosis may occur; however, with the stringent criteria of catastrophic illness certification, the bias should be minimal as these patients would be reviewed thoroughly by the review board before the certificates were issued. Second, the number of malignancy and ILD cases in our DM/PM patients may not represent the actual number if these diagnoses were made or the patients received treatment at other hospital. Third, owing to the lack of standardized malignancy screening protocol, missing data did exist. Moreover, the types/numbers of the tumor markers checked were not uniform in this retrospective study; this would cause bias in the data interpretation. The majority of excluded patients had not been checked for any tumor markers. The incidence of ILD seemed to be lower in the excluded group compared with the enrolled subjects (15.1% vs 40.1%). Therefore, the enrolled study population may overestimate the association of tumor markers and ILD in DM/PM patients. Fourth, the trend of malignancy observed in this study may not represent the trend in Taiwan as the data analyzed was not a population-based database. Therefore, an upcoming study looking for an up-to-date malignancy trend in DM/PM in Taiwan population is essential. Finally, the newer investigation modalities such as PET/CT, anti-TIF1 gamma, anti-MDA5, anti-NXP2 and KL-6 were not included due to their availability in Taiwan. A future study on these modalities together with the conventional markers should be compared in order to provide us more complete information.

Conclusion {#section22-2050312118781895}
==========

In conclusion, we have demonstrated that tumor markers were not useful in malignancies screening for DM/PM patients in this tertiary center. Instead, the screening should comprise other investigation modalities such as examinations of the nasopharynx, gynecology, radiology or histopathology according to the clinical symptoms and the most prevalent malignancy in different geographical areas and ethnics. In addition, CA15-3 may be a promising indicator for detecting the presence of ILD in DM/PM patients, yet requires further confirmation by a larger and long-term study.
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